Evidence map›Paper›PMID 36518323›Full record

ArticleFrontiers in oncology2022

Proton therapy for isolated local regional recurrence of breast cancer after mastectomy alone.

Brady S Laughlin, Ronik S Bhangoo, Joshua R Niska, Cameron S Thorpe, Marlene E Girardo, Justin D Anderson, Heidi E Kosiorek, Lisa A McGee, William F Hartsell, John H Chang and 4 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 59% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 1 country.

Brady S LaughlinDepartment of Radiation Oncology Mayo Clinic, Phoenix, AZ, United States.
Ronik S BhangooDepartment of Radiation Oncology Mayo Clinic, Phoenix, AZ, United States.
Joshua R NiskaDepartment of Radiation Oncology Mayo Clinic, Phoenix, AZ, United States.
Cameron S ThorpeDepartment of Radiation Oncology Mayo Clinic, Phoenix, AZ, United States.
Marlene E GirardoHealth Sciences Research, Division of Biostatistics, Mayo Clinic, Scottsdale, AZ, United States.
Justin D AndersonDepartment of Radiation Oncology Mayo Clinic, Phoenix, AZ, United States.
Heidi E KosiorekHealth Sciences Research, Division of Biostatistics, Mayo Clinic, Scottsdale, AZ, United States.
Lisa A McGeeDepartment of Radiation Oncology Mayo Clinic, Phoenix, AZ, United States.
William F HartsellNorthwestern Medicine Chicago Proton Center, Warrenville, IL, United States.
John H ChangProCure Proton Therapy Center, Oklahoma City, OK, United States.
Carl J RossiScripps Proton Therapy Center, San Diego, CA, United States.
Henry K TsaiProCure Proton Therapy Center, Somerset, NJ, United States.
Isabelle J ChoiNew York Proton Center, New York, NY, United States.
Carlos E VargasDepartment of Radiation Oncology Mayo Clinic, Phoenix, AZ, United States.
Mayo Clinic in Florida · USWinnMed · USMayo Clinic in Arizona · USProCure (United States) · USNew York Proton Center · USNorthwestern Medicine · USScripps Institution of Oceanography · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose/Objectives: To assess adverse events (AEs) and disease-specific outcomes after proton therapy for isolated local-regional recurrence (LRR) of breast cancer after mastectomy without prior radiotherapy (RT). Materials/Methods: Patients were identified from a multi-institutional prospective registry and included if diagnosed with invasive breast cancer, initially underwent mastectomy without adjuvant RT, experienced an LRR, and subsequently underwent salvage treatment, including proton therapy. Follow-up and cancer outcomes were measured from the date of RT completion. Results: Nineteen patients were included. Seventeen patients were treated with proton therapy to the chest wall and comprehensive regional lymphatics (17/19, 90%). Maximum grade AE was grade 2 in 13 (69%) patients and grade 3 in 4 (21%) patients. All patients with grade 3 AE received > 60 GyE (p=0.04, Spearman correlation coefficient=0.5). At the last follow-up, 90% of patients were alive with no LRR or distant recurrence. Conclusions: For breast cancer patients with isolated LRR after initial mastectomy without adjuvant RT, proton therapy is well-tolerated in the salvage setting with excellent loco-regional control. All grade 3 AEs occurred in patients receiving > 60 GyE.

Indexed as

breast cancerlocal recurrencePMRTpost-mastectomy radiotherapyprotons

Identifiers

PMID36518323
PMCPMC9742552
OpenAlexW4310235047

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.